Barclays initiated coverage of Omada Health (OMDA) with an Overweight rating and $21 price target. Omada’s digital health solution is addressing a large market given the prevalence of prediabetes, diabetes, hypertension and musculoskeletal issues, says the analyst, who thinks the company’s GLP-1 Care Track offerings could be an accelerant to adoption. The firm thinks Omada is gaining share in this cardiometabolic market, particularly from Teladoc’s (TDOC) Livongo, the analyst added.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMDA:
- Omada Health initiated with an Overweight at Morgan Stanley
- Omada Health initiated with a Buy at Goldman Sachs
- JPMorgan Issues Buy Rating for Omada Health, Inc. Citing Growth Potential in Underpenetrated $135 Billion Market and Strategic Partnerships
- Omada Health: A Compelling Investment Opportunity in Digital Health with Strong Growth Potential
- Omada Health: Strong Growth Prospects and Path to Profitability with Undervalued Potential